Navigation Links
Animal model for schizophrenia identifies a novel approach for treating cognitive impairments
Date:6/9/2009

Philadelphia, PA, 9 June 2009 - Researchers have been seeking a safe and effective way to treat cognitive impairments associated with schizophrenia by enhancing N-methyl-D-aspartate (NMDA) glutamate receptors. Functional deficits in NMDA receptors may contribute to the underlying neurobiology of this disorder. The first generation of studies trying to stimulate NMDA receptors administered large amounts of substances, like glycine or D-serine, which indirectly enhance NMDA receptor function. While there were some positive reports of efficacy, findings across studies were more inconsistent than was hoped.

New approaches following this line of research are just beginning to be tested in patients. For example, several pharmaceutical companies are studying drugs that block the glycine transporter (GlyT1) and thereby raise synaptic glycine levels. A new study in Biological Psychiatry, published by Elsevier, by Dr. Kenji Hashimoto and colleagues may represent a "next step," which is to prevent the inactivation of D-serine by the enzyme D-amino acid oxidase (DAAO). The authors found that this approach enhances the efficacy of D-serine in an animal model for deficits in NMDA glutamate receptor function.

To put it more simply, although D-serine is used as a treatment for schizophrenia, it is metabolized by DAAO, reducing its availability in the brain. So, using an animal model of schizophrenia, these scientists co-administered D-serine and a compound that blocks the effects of DAAO. This increased the levels of D-serine in the mice and therefore its effectiveness in treating the abnormal behaviors in this animal model that may be relevant to schizophrenia.

"We still do not have effective treatments that specifically target the cognitive and functional impairments associated with schizophrenia. These findings are very interesting because there is a continued sense that we have not yet captured the therapeutic promise associated with the glycine site of the NMDA receptor. GlyT1 blockers and DAAO inhibitors may be important new clinical research tools," comments John Krystal, M.D., Editor of Biological Psychiatry.

Further research is still needed to see whether these findings can be extended to humans, but it is hoped that this combination therapy proves to be a novel and effective treatment of schizophrenia.


'/>"/>

Contact: Jayne Dawkins
ja.dawkins@elsevier.com
215-239-3674
Elsevier
Source:Eurekalert

Related medicine news :

1. Nasal Anthrax Vaccine Proves Effective in Animal Study
2. Molecular probe paints cancer cells in living animals, Stanford researchers find
3. USC researcher identifies stem cells in tendons that regenerate tissue in animal model
4. UCSF animal care facility receives top accreditation
5. Why are some groups of animals so diverse?
6. Penn Veterinary Medicine report new strategy to create genetically modified animals
7. ABC TV San Francisco Features Canine Cancer Research Story: Saving Our Dogs, Helping Humans Beat Cancer - Work at Morris Animal Foundation, UC-Davis
8. Scientists get first look at nanotubes inside living animals
9. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
10. Fort Dodge Animal Health and the American Association of Feline Practitioners Launch Educational Web Site for Cat Owners - www.healthycatsforlife.com
11. American Humane Association Adds Direct Services in Animal-Assisted Activities and Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... York, NY (PRWEB) , ... June 20, 2017 , ... ... today their continued expansion and success in the clinical trials market. Similar to its ... a track record in the clinical trials marketplace by proving the value of eVisits ...
(Date:6/20/2017)... ... June 20, 2017 , ... With certifications and experience that puts them at ... Adam and Hal Kimowitz are currently accepting new patients at their practice for these ... for some patients, which is why they offer the latest in modern dental techniques ...
(Date:6/20/2017)... ... June 20, 2017 , ... Uniform Advantage (UA), a ... new products designed to create tailored looks and athleisure-inspired outfits. UA Flex fabric is ... care stretch twill. , With trendy looks hitting the medical community, UA Flex is ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... would like to officially welcome Anthony Stanowski, DHA, FACHE to the MEDI+SIGN Advisory ... insight and expertise in healthcare will provide invaluable direction for the company,” says ...
(Date:6/19/2017)... ... ... The joyful summer wedding season is upon us, but it’s also mosquito ... wet spring have created ideal conditions for mosquitoes and ticks poised to swoop in ... when a bride and groom are saying their "I do's,” observes Manuel Castro, co-founder ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... 50 years ago today, the Monterey Pop Festival opened its ... San Francisco "Summer of Love."  To celebrate the anniversary, Northern ... strategic market research portals that it will begin delivering to ... Light,s "Summer of Love (For Our Customers)."  ... Northern ...
(Date:6/14/2017)... , June 14, 2017 The Bio Supply ... City of Fremont and the Biomedical ... bio-pharma industry in California by ... executive networking, and fostering workforce development. The primary focus ... growth of start-ups, as well as small and mid-sized ...
(Date:6/13/2017)... WARSAW, Ind. , June 13, 2017 Zimmer ... in musculoskeletal healthcare, today announced that the U.S. Food and ... Letter dated June 3, 2015 relating to its ... "The successful clearance of ... China manufacturing facility is a measure of the ...
Breaking Medicine Technology: